Medicus Pharma Ltd. (MDCX)

NASDAQ: MDCX · Real-Time Price · USD

0.16+0.00 (+0.63%)

Market Cap	11.49M-93.4%
Revenue (ttm)	n/a
Net Income	-56.66M
EPS	-2.38
Shares Out	71.71M
PE Ratio	n/a
Forward PE	-0.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,835,394
Open	0.16
Previous Close	0.16
Day's Range	0.16 - 0.16
52-Week Range	0.14 - 2.78
Beta	-0.30
Analysts	none
Price Target	4.50(+2708.99%)
Earnings Date	n/a

+0.50% (1D)

No price history available.

Full Chart

Alerts Compare

Insider Score

––Not scored

MDCX Insider Score

Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.

See stocks that are scored

About MDCX

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.

Address

300 Conshohocken State Road, West Conshohocken, PA, 19428, United States

Market Cap

11 million

Employees

Industrial Classification

Drug Manufacturers - General

1 Day

+0.63%

5 Days

-0.62%

1 Month

-5.88%

6 Months

-65.67%

1 Year

-93.39%

$MDCX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Whale Activity →

Recently reported changes in MDCX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MDCX's directors and management

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MDCX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New MDCX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MDCX from public contracts

Source: USAspending.gov

MDCX Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

No Insider Score for MDCX yet — no open-market insider buys or sells in the last 90 days.

Bull Case vs Bear Case

AI-generated from MDCX’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys

Sells

Buy Value

Distinct Buyers

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.